$CMND Cashflow Statement | Understand Stock

$CMND

$6.06 +$0.09 (1.55%) Close

$CMND Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Oct 31, 2025	FY2024 12 months to Oct 31, 2024	FY2023 12 months to Oct 31, 2023	FY2022 12 months to Oct 31, 2022
Operating activities
Net loss
Adjustments for:
Amortization of intangible assets
Depreciation of property and equipment
Amortization of right-of-use asset
Interest on lease liability

Non-cash financing and investing activities
Common shares issued to Xylo Technologies Ltd. (formerly known as Medigus Ltd.)
Right of use assets obtained in exchange for lease liabilities
Early termination of office lease (Note 4)
Shares obtained from Xylo Technologies Ltd. (formerly known as Medigus Ltd.) in issuance of shares and warrants
Deferred offering costs included in non-current assets
Early termination of office lease
Issuance of shares upon conversion of convertible loans (Notes 8,9c(iii))
Exchange rate differences
Issuance costs allocated to derivate warrants liability
Issuance costs allocated to derivate warrant liability
Depreciation of property and equipment
Changes in fair value of derivative warrant liabilities
Change in fair value of convertible loans
Share-based compensation
Changes in fair value of short-term investments
Tax expenses

Decrease (increase) in amounts receivable
Changes in fair value of short-term investments
Tax expenses
Changes in working capital:
Decrease (increase) in other receivables
Decrease (increase) in prepaid expenses
Increase (decrease) in accounts payable and accrued liabilities
Increase (decrease) in due to related parties
Increase (decrease) in amounts due to / from related parties
Net cash used in operating activities

Investing activities
Proceeds from sale of short-term investment (Note 5)
Purchase of securities (Note 5)
Proceeds from purchase of short-term investment (Note 5)
Changes in restricted cash
Acquisition of property and equipment
Net cash used in investing activities

Financing activities
Proceeds from issuance of common shares and warrants, net of issuance costs
Proceeds received from exercise of warrants (Note 7)
Interest paid
Proceeds received from issuance of convertible loans (Note 8)
Repayment of lease liabilities
Net cash provided by financing activities

Effect of foreign exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Shares obtained from Medigus in issuance of shares and warrants (Note 8c)
Deferred offering costs included in non-current assets
Supplementary disclosure of cash flow information:
Cash received as interest
Dividend received
Cash paid in respect of taxes
Interest on lease liability

Comments